RGL-305+ Lymphoma + Exploratory Clinical Study

This study is testing an experimental drug called RGL-305 in patients with lymphoma who have responded to previous treatment but still have trace amounts of cancer detectable by sensitive tests (called MRD-positive). The goal is to see if RGL-305 can eliminate that remaining cancer. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with lymphoma confirmed by biopsy - You have received at least one prior standard treatment and had a complete or partial response, but still have detectable cancer by MRD testing - Your overall health is good (ECOG 0–1) - Your expected survival is at least 3 months - Your blood counts, liver, and heart function meet required levels **You may NOT be eligible if...** - You have not had prior lymphoma treatment - You have active, uncontrolled infection - You are pregnant or breastfeeding - Your organ function does not meet required thresholds Talk to your doctor to see if this trial is right for you.